Market Overview

Here's What's Going On With Puma Biotech's Secondary Offering

Share:
Here's What's Going On With Puma Biotech's Secondary Offering
Related
Credit Suisse Says Gr3 Diarrhea Still A Concern For Puma Biotech, But Pullback Is Overdone
Puma Biotech Crashes After Bad News About Its Breast Cancer Drug

Puma Biotechnology Inc (NYSE: PBYI) shares were trading steadily lower Wednesday. Earlier in the day, traders were passing around unconfirmed chatter that at these levels, Puma's secondary offering might be pulled.

TheStreet's Adam Feuerstein, arguably the most noted biotech reporter around, Tweeted that he's "hearing weak investor demand for stock offering announced last night."

Earlier Wednesday afternoon, sources close to Puma's secondary offering told Benzinga Pro that investor demand is "very weak," and were hearing bids have been in the range of $40-$42 per share for only half the offering. Sources suggested bankers will hold a call with Puma at 2 p.m. ET to consider the fate of the secondary.

Benzinga Pro heard from another source close to the deal that Puma Biotech is discussing a debt deal instead of an equity deal. For a little background, a debt deal involves borrowing money to be repaid, plus interest; Equity deal involves raising money by selling interests in the company.

Shares of Puma Biotech traded recently at $42.85, down more than 18 percent on the day.

Update, 3:33 p.m. ET: Source close to the secondary deal tells Benzinga that Puma will go ahead with the offering. The deal is not fully covered, but is expected to be in the $40-$42 per share range.

pbyi.png

Posted-In: News Rumors Offerings Top Stories Best of Benzinga

 

Related Articles (PBYI)

View Comments and Join the Discussion!